#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mucopolysaccharidosis II VEXAS syndrome Chronic cutaneous lupus erythematosus Cystic fibrosis Turner's syndrome Parkinson's disease Ataxia telangiectasia Henoch-Schonlein purpura nephritis Hairy cell leukaemia recurrent Solitary fibrous tumour Follicular lymphoma stage I Polymyositis Chronic graft versus host disease in intestine Growth hormone deficiency Extraskeletal ossification More trials…

    Learn about Rare Diseases

    Sarcoidosis – Diagnostics Castleman’s disease – Diagnostics Cystic fibrosis – Life with Disease Lennox-Gastaut syndrome – Trials in Disease Lymphatic malformation – Treatment Haemophilia – Life with Disease Indolent systemic mastocytosis – Life with Disease Primary hyperoxaluria – Life with Disease Von Willebrand’s disease – Life with Disease Anaplastic thyroid cancer – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sodium Glycerophosphate Alternaria Alternata (402) Ag-946 Phosphate Glucose, Anhydrous Fexofenadine Hepatitis B Surface Antigen Mirikizumab Cefixime ZINC Specific Nucleic Acid Sna-Xfsb ALXN2420 Remifentanil Ltx-315 Taurine Lolium Perenne AZD0120 Allopurinol Avapritinib VMX-C001 Cytisinicline More therapies…

    Learn about Your Condition

    Haemofiltration Chorea Coronary artery disease Acute HIV infection Iron deficiency anaemia Limb reduction defect Complex regional pain syndrome Systemic lupus erythematosus Pneumococcal infection Anal cancer recurrent Sickle cell anaemia Neuropathic arthropathy Mucopolysaccharidosis Post procedural oedema Colon cancer stage II More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San…

Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania

Vcm Srjbd Sovyp 7bm Cmckmciz 9vqayy Iqsaf

Want to learn more about this study or check if you can participate? Contact us.

  • Study of levofloxacin, ketorolac trometamol, and dexamethasone eye drops for preventing inflammation and infection after cataract surgery in adults

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Dexamethasone
    • KETOROLAC TROMETAMOL
    • Levofloxacin
    Greece Italy Poland Spain Sweden

  • Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Factor IX deficiency
    • Factor VIII deficiency
    • Haemophilia A without inhibitors
    Investigated Drugs:
    • Concizumab
    Bulgaria France Greece Italy Lithuania Norway +4

  • Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

    Recruiting

    3 1 1
    Investigated Drugs:
    • Depemokimab
    Belgium Bulgaria Czechia France Germany Ireland +3

  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elotuzumab
    • Cevostamab
    • Carfilzomib
    Czechia Denmark France Germany Greece Italy +2

  • A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Belgium Bulgaria Czechia France Germany Greece +4

  • A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Topotecan Hydrochloride
    Austria Belgium Czechia Denmark France Germany +5

  • A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Risankizumab
    • Guselkumab
    Austria Belgium Czechia Denmark France Germany +7

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Nipocalimab
    Bulgaria Czechia Denmark Finland France Germany +9
1 2 3 … 31
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!